Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging

By D. Bartlett, H. Su, I. Hildebrandt, W. Weber, Mark E. Davis. Proceedings of the National Academy of Sciences of the United States of America, 2007

795 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Dependence of Nanoparticle Toxicity on Their Physical and Chemical Properties (2018, background): “In addition to gold NPs, those based on micelles, liposomes [11], and polymers with attached “capture molecules” [12] are already used as drug carriers.”
The delivery of therapeutic oligonucleotides (2016, background): “In contrast to the lack of information at the cellular level, there is substantial data on the pharmacokinetics and biodistribution of polymeric nanoparticles (193,230).”
RNA-based Therapeutics- Current Progress and Future Prospects (2012, background): “…applications that require targeted systemic delivery, synthetic carriers may be decorated with cell-specific ligands or aptamers that allow receptor-mediated uptake (Bartlett et al., 2007), and biodegradable nanoparticle carriers allow for slow drug release once inside the cell (Li et al., 2010).”
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, background): “Together, these factors explain why active targeting strategies cannot radically change the biodistribution profiles of nanomaterials [157-159] and why the blood circulation times of ligand-decorated NPs need to be optimized to achieve optimal targeting [4, 33, 160].”